Drug Type T cell engagers (TCE) |
Synonyms- |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MAGEA1 inhibitors(Melanoma-associated antigen 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | IND Approval | United States | 05 Dec 2025 | |
| Solid tumor | Preclinical | China | 29 May 2024 |






